Evidence map›Paper›PMID 39397434›Full record

ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)2025

Brief Communication: Combination of an MIP3α-Antigen Fusion Therapeutic DNA Vaccine With Treatments of IFNα and 5-Aza-2'Deoxycytidine Enhances Activated Effector CD8+ T Cells Expressing CD11c in the B16F10 Melanoma Model.

Kaitlyn Fessler, Jiaqi Zhang, Avinaash K Sandhu, Yinan Hui, Aakanksha R Kapoor, Samuel K Ayeh, Styliani Karanika, Petros C Karakousis, Richard B Markham, James T Gordy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunotherapy (Hagerstown, Md. : 1997), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Kaitlyn FesslerDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Jiaqi ZhangDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Avinaash K SandhuDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Yinan HuiDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Aakanksha R KapoorDepartment of Medicine, Division of Infectious Diseases, Center for Tuberculosis Research, The Johns Hopkins Hospital, Baltimore, MD.
Samuel K AyehDepartment of Medicine, Division of Infectious Diseases, Center for Tuberculosis Research, The Johns Hopkins Hospital, Baltimore, MD.
Styliani KaranikaDepartment of Medicine, Division of Infectious Diseases, Center for Tuberculosis Research, The Johns Hopkins Hospital, Baltimore, MD.
Petros C KarakousisDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Richard B MarkhamDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
James T GordyDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.ORCID 0000-0003-2588-0756

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persistersR01AI148710 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KARAKOUSIS, PETROS C, MARKHAM, RICHARD B. · 2020 to 2024
$3.8M
Mentoring in Immunometabolic Dysregulation in TB and TB/HIVK24AI143447 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KARAKOUSIS, PETROS C · 2019 to 2024
$956k
Mechanisms of a therapeutic DNA vaccine targeting Mycobacterium tuberculosis persistersK08AI174959 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Styliani Karanika · 2024 to 2026
$603k
NCI NIH HHS P30 CA006973NIAID NIH HHS K08 AI174959NIAID NIH HHS K24 AI143447NIAID NIH HHS R01 AI148710
6 · The paper itself

Abstract

Previous studies in the B16F10 mouse melanoma model have demonstrated that combining a DNA vaccine comprised of regions of gp100 and tyrosinase-related protein 2 fused to macrophage-inflammatory protein 3-alpha (MIP3α) with recombinant interferon alpha (IFN) and 5-Aza-2'-deoxycytidine (5Aza) treatments resulted in significantly greater antitumor activity and immunogenicity in the tumor microenvironment (TME). This brief report details that the combination of vaccine with treatments IFN and 5Aza results in an increase in the TME of a distinct CD11c+ CD8+ T-cell population. This cell population correlates with tumor size, is primarily comprised of effector or effector memory T cells, and has a more robust response to ex vivo stimulation as compared with CD11c- CD8+ T cells. In conclusion, this combination therapy results in a greater presence of highly active effector CD8+ T cells expressing CD11c in the TME, which are likely primary contributors to treatment efficacy.

Indexed as

CD11c AntigenCD8-Positive T-LymphocytesDecitabineInterferon-alphaMelanoma, ExperimentalTumor MicroenvironmentVaccines, DNAAnimalsAzacitidineCancer VaccinesCell Line, TumorDisease Models, Animalgp100 Melanoma AntigenHumansIntramolecular OxidoreductasesLymphocyte ActivationAzacitidineCancer VaccinesCD11c AntigenDecitabinedopachrome isomerasegp100 Melanoma AntigenInterferon-alphaIntramolecular OxidoreductasesRecombinant Fusion ProteinsVaccines, DNA

Identifiers

PMID39397434
PMCPMC11617275

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.